Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1996 to 2010 of 8933 results

  1. Nitisinone for treating alkaptonuria [ID2691]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Remimazolam for general anaesthesia [ID3796]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Prolonged-release diazoxide choline for treating Prader-Willi syndrome [ID1389]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Canakinumab for untreated Schnitzler syndrome [ID4063]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations [TSID12011]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Lanadelumab for preventing recurrent attacks of hereditary angioedema in people 2 years and over [TSID12298]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Infrared lasers for treating onychomycosis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Noninvasive Vagus Nerve Stimulation For reactive airway disease

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. NEMOST growing domino for Neuromuscular early onset scoliosis with Risser 0 in first surgical intention

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation